Revolution Medicines (RVMD) Q4 FY24 earnings call

Revolution Medicines continues to advance its pioneering RAS(ON) inhibitor pipeline, initiating multiple pivotal trials for daraxonrasib in pancreatic and non-small cell lung cancers, including novel earlier-line and adjuvant settings. The company is also progressing its mutant-selective inhibitors and earlier-stage programs, supported by a strong financial position and growing commercial capabilities, aiming to revolutionize treatment for RAS-addicted cancers.